Voya Investment Management LLC Acquires 735 Shares of argenex SE $ARGX

Voya Investment Management LLC raised its stake in shares of argenex SE (NASDAQ:ARGX) by 5.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,905 shares of the company’s stock after purchasing an additional 735 shares during the period. Voya Investment Management LLC’s holdings in argenex were worth $8,822,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ARGX. Wealth Management Associates Inc. acquired a new stake in shares of argenex in the 1st quarter valued at $268,000. Geneos Wealth Management Inc. raised its stake in argenex by 550.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after acquiring an additional 99 shares during the period. Focus Partners Wealth increased its position in argenex by 22.3% during the 1st quarter. Focus Partners Wealth now owns 400 shares of the company’s stock worth $237,000 after buying an additional 73 shares during the period. Flaharty Asset Management LLC bought a new position in shares of argenex in the first quarter worth $180,000. Finally, Woodline Partners LP boosted its stake in shares of argenex by 21.0% during the first quarter. Woodline Partners LP now owns 89,796 shares of the company’s stock valued at $53,147,000 after purchasing an additional 15,559 shares in the last quarter. 60.32% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on ARGX shares. Bank of America boosted their price target on argenex from $880.00 to $887.00 and gave the company a “buy” rating in a research note on Tuesday, September 2nd. Morgan Stanley upped their price target on argenex from $700.00 to $766.00 and gave the company an “overweight” rating in a research report on Friday, August 1st. Wall Street Zen lowered argenex from a “buy” rating to a “hold” rating in a research note on Sunday. Guggenheim increased their price objective on argenex from $1,060.00 to $1,070.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Finally, Wells Fargo & Company raised their price target on argenex from $741.00 to $756.00 and gave the stock an “overweight” rating in a research report on Thursday, July 31st. Two analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, argenex currently has a consensus rating of “Buy” and a consensus target price of $784.32.

argenex Trading Down 0.6%

argenex stock opened at $752.32 on Wednesday. argenex SE has a 12 month low of $510.05 and a 12 month high of $779.03. The firm has a market cap of $46.04 billion, a price-to-earnings ratio of 38.58, a PEG ratio of 0.82 and a beta of 0.41. The stock has a fifty day simple moving average of $658.22 and a two-hundred day simple moving average of $608.70.

argenex (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, July 31st. The company reported $3.74 EPS for the quarter, topping the consensus estimate of $2.84 by $0.90. argenex had a return on equity of 21.06% and a net margin of 40.98%.The company had revenue of $866.79 million during the quarter, compared to analyst estimates of $776.82 million. On average, equities research analysts forecast that argenex SE will post 3.13 EPS for the current fiscal year.

argenex Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.